Meet the team reimagining antibody discovery
Through scientific excellence, strong partnerships, and a collective drive for impact, we are pushing the boundaries of antibody discovery to unlock therapeutic opportunities once considered beyond reach.
OUR STORY
Transforming biological insight into therapeutic innovation
Panosome is a biotechnology company and spin-off from the German Cancer Research Center (DKFZ).
Our journey began with a simple yet powerful insight: one of nature’s most immunogenic surfaces could be transformed into a revolutionary platform for antibody discovery. Today, we are leveraging this innovation to create high-affinity antibodies against targets previously considered inaccessible, with the goal of delivering meaningful impact for patients worldwide.
Our Mission
To transform antibody development by discovering and generating highly specific antibodies against challenging targets and advancing them toward life-changing therapies.
Our Vision
To make the untargetable targetable, unlocking new possibilities for patients through advancing the next generation of antibody therapeutics.
Our Team
The people behind Panosome
Management
Team Member
Strategic Advisors
Advancing antibody innovation together
Our collaborative network spans leading research institutions, strategic investors, and public funding organizations, enabling us to accelerate scientific innovation and therapeutic development.
Recognition that fuels our mission
Our innovative approach to antibody discovery has been recognized by several scientific and funding organizations, highlighting the impact and potential of our platform.
Rooted in Heidelberg's innovation ecosystem
Located in one of Europe’s leading life science hubs, Panosome benefits from close connections to world-class scientific research, biotechnology entrepreneurship, and clinical translation.